Sulforaphane Targets Multiple Pathological Processes in Friedreich Ataxia Patient-Induced Pluripotent Stem Cell-Derived Sensory Neurons
Antioxidants & Redox Signaling · 2025-08 · 43 (4-6) · 308-327
DOI: 10.1089/ars.2024.0756 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants & Redox Signaling, online erschienen am 04.08.2025. Verfasst von Wenyao Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Sciences, Swinburne University of Technology, Hawthorn, Victoria, Australia. Hauptthemen laut MEDLINE: Isothiocyanates, Friedreich Ataxia, Sulfoxides, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 94 Literaturangaben.
Abstract (Originalsprache)
Aims
In Friedreich ataxia (FRDA), early motor discoordination stems from dysfunctional sensory neurons in the spinal cord driven by epigenetic dysregulation, frataxin (FXN) deficiency, oxidative stress, and inflammation. Omaveloxolone, a nuclear factor erythroid 2-related factor-2 (NRF2) inducer, is the only treatment available. In various chronic disease models, sulforaphane (SF) can target NRF2 and the above processes. This study compared the effects of SF with omaveloxolone and dimethyl fumarate (DMF) in sensory neurons generated from FRDA patient-induced pluripotent stem cells and their isogenic control.
Results
The successful generation of the FRDA and isogenic control sensory neurons was confirmed by the positive expression of β-III TUBULIN, BRN3A, ISLET1, PERIPHERIN, and tropomyosin receptor kinase C. In comparison with the isogenic control, FRDA sensory neurons displayed an aberrant gene expression profile alike to that reported in patients. None of the drugs affected the viability of the isogenic control sensory neurons. SF treatment improved the viability of FRDA sensory neurons by up to 61% versus the untreated control. DMF treatment showed a modest 35% increase, while omaveloxolone lacked an effect. SF-treated FRDA sensory neurons demonstrated increased reduced glutathione/oxidized glutathione ratio and expression of FXN and redox markers, and a reduced expression of selected epigenetic enzymes and inflammatory cytokines, at the respective gene and protein levels. DMF and omaveloxolone treatments only modulated some of these biomarkers. Innovation: We revealed the therapeutic potential of SF and how it performs in comparison with omaveloxolone and DMF, in a physiologically and genetically relevant in vitro FRDA model.
Conclusion
SF offers a multipronged approach to alleviating the different cellular events underlying FRDA. Antioxid. Redox Signal. 43, 308–327.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Health Sciences, Swinburne University of Technology, Hawthorn, Victoria, Australia.
- Melbourne School of Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
- Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.
- Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Faith Kwa
Zitieren
APA
Yang, W., Thompson, B., Miellet, S., Maddock, M., Napierala, M., Dottori, M., & Kwa, F. (2025). Sulforaphane Targets Multiple Pathological Processes in Friedreich Ataxia Patient-Induced Pluripotent Stem Cell-Derived Sensory Neurons. Antioxidants & Redox Signaling, 43(4-6), 308-327. https://doi.org/10.1089/ars.2024.0756
Vancouver
Yang W, Thompson B, Miellet S, Maddock M, Napierala M, Dottori M, et al. Sulforaphane Targets Multiple Pathological Processes in Friedreich Ataxia Patient-Induced Pluripotent Stem Cell-Derived Sensory Neurons. Antioxidants & Redox Signaling. 2025;43(4-6):308-327. doi:10.1089/ars.2024.0756
BibTeX
@article{Yang2025,
author = {Yang, Wenyao and Thompson, Bruce and Miellet, Sara and Maddock, Marnie and Napierala, Marek and Dottori, Mirella and Kwa, Faith},
title = {Sulforaphane Targets Multiple Pathological Processes in Friedreich Ataxia Patient-Induced Pluripotent Stem Cell-Derived Sensory Neurons},
journal = {Antioxidants & Redox Signaling},
year = {2025},
volume = {43},
number = {4-6},
pages = {308--327},
doi = {10.1089/ars.2024.0756}
}
EUVIMED